Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE-CRC-03 metastatic colorectal cancer study
2025-524648-37-00Phase 3Authorised
- Sponsor
- Merck KGaA
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of precemtabart tocentecan in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Merck KGaA. Primary endpoints: overall survival (OS) Arm 1, overall survival (OS) Arm 2 and 1 more. Planned start Aug 2026; status: authorised.
02
Drugs
precemtabart tocentecan
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-524648-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524648-37-00.